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rch 11, 2014.his study sought to determine how often patients with primary prevention implantable cardioverter-deﬁbrillators
(ICDs) meet guideline-derived indications at the time of generator replacement.Background Professional societies have developed guideline criteria for the appropriate implantation of an ICD for the primary
prevention of sudden cardiac death. It is unknown whether patients continue to meet criteria when their devices
need replacement for battery depletion.Methods We performed a retrospective chart review of patients undergoing replacement of primary prevention ICDs at
2 tertiary Veterans Affairs Medical Centers. Indications for continued ICD therapy at the time of generator
replacement included a left ventricular ejection fraction (LVEF) 35% or receipt of appropriate device therapy.Results In our cohort of 231 patients, 59 (26%) no longer met guideline-driven indications for an ICD at the time of generator
replacement. An additional 79 patients (34%) had not received any appropriate ICD therapies and had not
undergone reassessment of their LVEF. Patients with an initial LVEF of 30% to 35% were less likely to meet
indications for ICD therapy at the time of replacement (odds ratio: 0.52; 95% conﬁdence interval: 0.30 to 0.88;
p ¼ 0.01). Patients without ICD indications subsequently received appropriate ICD therapies at a signiﬁcantly lower
rate than patients with indications (2.8% vs. 10.7% annually, p < 0.001). If ICD generator explantations were
performed instead of replacements in the patients without ICD indications, the cost savings would be $1.6 million.Conclusions Approximately 25% of patients who receive primary prevention ICDs may no longer meet guideline indications for
ICD use at the time of generator replacement, and these patients receive subsequent ICD therapies at a signiﬁcantly
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tality in patients with reduced left ventricular function in
the absence of previous sustained ventricular arrhythmias
(1–3), a treatment strategy referred to as primary preven-
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14; revised manuscript received March 6, 2014,Association/Heart Rhythm Society as well as the Centers
for Medicare & Medicaid Services have developed speciﬁc
guideline criteria that patients are required to fulﬁll to receive
an ICD for the primary prevention of sudden cardiac death
(SCD) (4). These guideline criteria do not distinguish
between patients receiving initial devices and those un-
dergoing generator replacement for battery depletion.See page 2395However, after the initial ICD implantation, the clinical
characteristics of patients may change. In particular, many
patients who receive primary prevention ICDs may ex-
perience improvement or recovery of the left ventricular
ejection fraction (LVEF) (5,6), and therefore no longer
meet indications for a primary prevention ICD at the time
of generator replacement.
Abbreviations
and Acronyms
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Patient Records System
CPT = Current Procedural
Technology
CRT = cardiac
resynchronization therapy
CRT-D = cardiac
resynchronization therapy
with a deﬁbrillator
CRT-P = cardiac
resynchronization therapy
without a deﬁbrillator
ICD = implantable
cardioverter-deﬁbrillator
ICM = ischemic
cardiomyopathy
LVEF = left ventricular
ejection fraction
NICM = nonischemic
cardiomyopathy
SCD = sudden cardiac death
VA = Veterans Affairs
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2389It is possible that patients who experience improvement
or recovery of LVEF may have no beneﬁt from continued
ICD therapy. Furthermore, multiple studies have shown
that device replacement is associated with signiﬁcant
morbidity and even mortality (7–9). Patients with ICDs may
also experience inappropriate therapies that have been shown
to have detrimental effects including progression of heart
failure, impaired psychological well-being, and impaired
survival (10,11). Because w30,000 replacement procedures
are performed in the United States annually (12), ICD
replacement also has a signiﬁcant healthcare cost (13,14). For
all of these reasons, research examining the appropriateness of
ICD replacement is long overdue.
In this study, we sought to determine how often guideline-
derived indications for primary prevention ICD therapy are
still present when patients undergo elective ICD generator
replacement. Additionally, we examined how often patients
who no longer have an indication for primary prevention
ICD at the time of generator replacement receive ICD
therapies compared with patients who meet these in-
dications. Finally, we sought to estimate the differential costs
of replacement versus potentially withholding replacement in
patients who no longer meet indications for primary pre-
vention ICD at the time of elective generator replacement.Methods
Study population. We performed a retrospective chart re-
view of all patients who underwent ICD replacement at the
Philadelphia Veterans Affairs (VA) Medical Center and the
VA Pittsburgh Healthcare System over a period of 7 years
(March 2006 through March 2013) to identify patients who
had an ICD initially implanted for primary prevention of
SCD on the basis of a low LVEF (35%). Within this
subgroup, we further identiﬁed patients who underwent ICD
replacement for battery depletion manifest by achievement
of the device elective replacement indicator or end-of-life
measure. These patients constituted our study cohort. Pa-
tients with any other indication for generator change such
as lead malfunction, recall, and upgrade to a dual-chamber
or cardiac resynchronization therapy (CRT) device before
battery replacement indication were excluded. Patients un-
dergoing their second or more generator change and those
who were pacemaker dependent were also excluded. We also
excluded patients who received the original device on the
basis of MUSTT (Multicenter Unsustained Tachycardia
Trial) criteria (i.e., LVEF 40% and inducible ventricular
tachycardia or ﬁbrillation at electrophysiological study).
Clinical records of all veteran patients are maintained in the
national VA-wide Computerized Patient Records System
(CPRS), and we were able to review the medical records
comprehensively for all study patients. The study was
approved by the Philadelphia VA Medical Center and VA
Pittsburgh Healthcare System Institutional Review Boards.
Data collection and deﬁnitions. Data collection included
patient characteristics such as age and race, the initialindication for ICD implantation,
the type of device implanted
(CRT with deﬁbrillator [CRT-D],
dual-chamber ICD, or single-
chamber ICD), the most recent
LVEF, and the presence or
absence of comorbid conditions
at baseline and at the time of
ICD replacement. Comorbid
conditions included chronic kid-
ney disease (stage III or greater),
dialysis dependence, cognitive
impairment, neoplastic disease,
atrial ﬁbrillation, hypertension,
diabetes, and history of stroke.
Pertinent medication use (beta-
blockers, angiotensin-converting
enzyme inhibitors or angiotensin
receptor blockers, and antiar-
rhythmic drugs) at baseline and
at the time of ICD replacement
was reviewed. Data were also
collected from device interroga-
tion records, which included de-
livery of appropriate therapies (shock or antitachycardia
pacing for ventricular arrhythmia) and inappropriate ther-
apies (shock or antitachycardia pacing for nonventricular
arrhythmia events). Conventional criteria validated in pre-
vious ICD trials (3) were used to categorize patients as
having ischemic cardiomyopathy (ICM) or non-ICM
(NICM).
At the time of the generator replacement, patients were
classiﬁed into 1 of 3 groups: 1) ICD therapy was considered
to be indicated for any patient whose LVEF was 35% on
the basis of assessment within 1 year of undergoing gener-
ator replacement or if the patient had received appropriate
therapy (shock or antitachycardia pacing) from their ICD
after initial implantation regardless of the LVEF; 2) ICD
therapy was considered not indicated in patients who
demonstrated an improvement in their LVEF to 40%
and had not received any appropriate therapies over the
lifetime of the original device; and 3) ICD therapy was
considered unclear in patients who had not received any
appropriate therapies over the lifetime of the original device
and had also not had a reassessment of their LVEF within
1 year of undergoing ICD generator replacement. LVEF
assessment was on the basis of echocardiographic or nu-
clear imaging studies.
Cost analysis. Three models were considered for the cost
analysis: 1) replace all ICD generators regardless of LVEF;
2) explant generators in the group of patients for whom ICD
therapy was considered not indicated; and 3) obtain echo-
cardiograms in the group of patients with unclear indications
for ICD, assume that the percent of patients for whom
ICD therapy was not indicated would be the same in this
group as in our overall cohort, and additionally explant
Table 1
Characteristics of Patients at Initial ICD Implantation
and at the Time of ICD Replacement
Initial
Implantation
(N ¼ 231)
Generator
Replacement
(N ¼ 231) p Value
Age, yrs 65  10 (66) 70  9 (70) <0.01
White race 184 (80) d d
ICM 159 (69) d d
NICM 72 (31) d d
LVEF, % 23  6 (25) 33  14 (30) <0.01
CRT-D 86 (37) d d
Comorbidities
Chronic kidney disease
(stage III or greater)
51 (22) 68 (29) <0.01
Hypertension 170 (74) 189 (82) <0.01
Diabetes 99 (43) 107 (46) <0.01
Atrial ﬁbrillation 37 (16) 56 (24) <0.01
History of stroke 33 (14) 37 (16) 0.13
Dialysis dependent 1 (<1) 2 (1) 0.50
Neoplastic disease 6 (3) 33 (14) <0.01
Cognitive impairment 5 (2) 9 (4) 0.13
Nursing facility resident 1 (<1) 2 (1) 0.50
Medication use
ACE inhibitor or ARB 198 (86) 194 (84) 0.39
Beta-blocker 177 (77) 200 (87) <0.01
Antiarrhythmic drug 29 (13) 37 (16) 0.10
Values are mean  SD (median) or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CRT-D ¼ cardiac
resynchronization therapy with a deﬁbrillator; ICD ¼ implantable cardioverter-deﬁbrillator;
ICM ¼ ischemic cardiomyopathy; LVEF ¼ left ventricular ejection fraction; NICM ¼ nonischemic
cardiomyopathy.
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(40%). Costs were estimated using Medicare physician
and facility payment rates for procedures and Current Pro-
cedural Technology (CPT) codes. The total cost of ICD
generator replacement (CPT code 33240) was estimated at
$22,891 (physician cost was $379.02 and outpatient fa-
cility cost was $22,512). Total cost of ICD generator
explantation (CPT code 33241) was estimated at $1,907.55
(physician cost was $224.55 and outpatient facility cost was
$1,683). Total cost of an echocardiogram (CPT code 93306)
was estimated at $580 (physician cost was $189.51 and fa-
cility cost was $390.49) (13,14).
Statistical analysis. The characteristics of patients at the
time of initial ICD implantation and ICD replacement were
compared with McNemar tests for categorical variables and
paired t tests for continuous variables. Characteristics of
patients who met or did not meet criteria for an ICD at the
time of replacement were compared using chi-square tests
for categorical variables and t tests for continuous variables.
We also performed a multivariable logistic regression anal-
ysis with selected variables with known or presumed effects
on cardiac remodeling and/or risk of ICD therapy, including
the presence of CRT, the etiology of cardiomyopathy,
comorbid conditions, medication use, and LVEF at initial
implantation to determine whether these could predict
whether patients would meet primary prevention ICD in-
dications at the time of generator change. Patients were
divided into tertiles of initial LVEF (<15%, 16% to
29%, and 30% to 35%) to facilitate comparisons between
groups. Continuous variables are presented as mean  SD.
A p value <0.05 was considered to be statistically signiﬁcant.Figure 1 ICD Indications at Elective Generator Replacement
In our cohort of 231 patients, an implantable cardioverter-deﬁbrillator (ICD) was
indicated in 93 patients (40%), not indicated in 59 patients (26%), and indications
were unclear in 79 patients (34%).Results
Baseline characteristics. Our study cohort comprised 231
patients. The mean time between the initial implantation of
an ICD and generator replacement was 61  11 months.
Characteristics and comorbidities of patients at the time of
the initial ICD implantation and at the time of ICD
replacement are compared in Table 1. Among the comor-
bidities, the prevalence of chronic kidney disease (51 of 231
[22%] vs. 68 of 231 [29%]; p < 0.01), atrial ﬁbrillation (37 of
231 [16%] vs. 56 of 231 [24%]; p < 0.01), hypertension (170
of 231 [74%] vs. 189 of 231 [82%]; p < 0.01), diabetes (99 of
231 [43%] vs. 107 of 231 [46%]; p < 0.01), and neoplastic
disease (6 of 231 [3%] vs. 33 of 231 [14%]; p < 0.001) was
signiﬁcantly greater at the time of ICD generator replace-
ment. Among the medications, only the rate of beta-blocker
use was signiﬁcantly greater at the time of ICD replacement
(177 of 231 [77%] vs. 200 of 231 [87%]; p < 0.01).
Indications and predictors of continued ICD use at
generator replacement. Of the 231 patients undergoing
generator replacement, primary prevention ICD therapy was
considered indicated in 93 patients (40%), not indicated in
59 patients (26%), and unclear in 79 patients (34%) (Fig. 1).
Of the 93 patients who fulﬁlled guideline criteria for an ICDat the time of generator replacement, 50 patients (54%)
continued to meet primary prevention indications, 35 pa-
tients (38%) had received appropriate ICD therapy in the
intervening years and continued to have an LVEF of 35%,
and 8 patients (8%) received appropriate ICD therapy but
Table 3
Selected Predictors of Meeting Indications for
an ICD at Time of Generator Replacement
OR (95% CI) p Value
Age, per 10 yrs 0.98 (0.94–1.02) 0.30
White race vs. other 0.87 (0.39–1.90) 0.73
Initial LVEF 30%–35% vs. <30% 0.52 (0.30–0.88) 0.01
ICM vs. NICM 1.89 (0.90–3.95) 0.09
CRT-D 0.95 (0.45–2.03) 0.90
Chronic kidney disease (stage III or greater) 0.90 (0.37–2.22) 0.82
Hypertension 1.00 (0.47–2.16) 0.99
Atrial ﬁbrillation 0.58 (0.26–1.27) 0.17
ACE-I or ARB prescribed 0.47 (0.16–1.41) 0.18
Beta-blocker prescribed 1.34 (0.49–3.89) 0.54
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Table 1.
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of generator replacement.
Characteristics of patients who continued to meet criteria
for an ICD at the time of replacement versus those who
no longer met criteria are compared in Table 2. Except for
a signiﬁcantly higher LVEF (25  11% vs. 49  9%;
p < 0.001), there was no other statistically signiﬁcant dif-
ference between the 2 groups. Using a multivariable logistic
regression analysis (Table 3), a baseline LVEF of 30% to
35% (compared with LVEF of <30%) was the only sig-
niﬁcant characteristic associated with a lower likelihood of
meeting primary prevention ICD criteria at the time of
generator replacement (odds ratio: 0.52; 95% conﬁdence
interval: 0.3 to 0.88; p ¼ 0.01). Patients with ICM tended
to be more likely than patients with NICM to meet criteria
for ICD at the time of generator replacement (odds ratio:
1.89; 95% conﬁdence interval: 0.90 to 3.95; p ¼ 0.09), but
this did not reach statistical signiﬁcance.
Subsequent ICD therapies. The 59 patients who no
longer met indications for primary prevention ICD therapy
at the time of generator replacement (but still underwent the
replacement) were followed for a mean of 3.5  2.0 years
(median, 3.1 years; total of 177 person-years) after generatorTable 2
Characteristics of Patients Who Met or Did Not
Meet Criteria for Primary Prevention ICD at the
Time of Generator Replacement
Met Guideline
Criteria for ICD
(N ¼ 93)
Did Not Meet
Guideline Criteria
for ICD
(N ¼ 59) p Value
Age, yrs 67  9 (65) 69  9 (67) 0.88
White race 68 (73) 46 (78) 0.63
Single- or dual-
chamber ICD
61 (66) 41 (69) 0.75
CRT-D 32 (34) 18 (31) 0.75
LVEF, % 25  11 (25) 49  9 (45) <0.001
ICM 54 (58) 35 (59) 0.88
Comorbidities
Chronic kidney
disease (stage III
or greater)
28 (30) 20 (34) 0.76
Hypertension 65 (70) 42 (71) 0.86
Diabetes 48 (52) 27 (46) 0.59
Atrial ﬁbrillation 30 (32) 13 (22) 0.24
History of stroke
or transient
ischemic attack
17 (18) 9 (15) 0.79
Dialysis dependent 1 (1) 1 (2) 0.74
Neoplastic disease 7 (8) 8 (14) 0.35
Cognitive
impairment
6 (6) 0 (0) 0.12
Nursing facility
resident
3 (3) 1 (2) 0.96
Medication use
ACE inhibitor or ARB 81 (87) 46 (78) 0.21
Beta-blocker 80 (86) 52 (88) 0.90
Antiarrhythmic drug 19 (20) 8 (14) 0.39
Values are mean  SD (median) or n (%).
Abbreviations as in Table 1.replacement. During this time, 5 patients (8%) received
appropriate ICD therapies (4 received shocks for ventricular
tachycardia or ventricular ﬁbrillation and 1 received anti-
tachycardia pacing for ventricular tachycardia). Thus, the
rate of subsequent appropriate ICD therapy in these pa-
tients who no longer met primary prevention ICD in-
dications at the time of generator replacement was 2.8% per
person-year. In comparison, patients who continued to meet
primary prevention ICD indications at the time of generator
replacement had a signiﬁcantly higher appropriate ICD
therapy rate of 10.7% per person-year (log-rank, p < 0.001).
Kaplan-Meier survival curves are shown in Figure 2.
Cost analysis. Using the ﬁrst model described in the
Methods section, the total cost of replacing all ICD gener-
ators regardless of the LVEF was estimated at $5,287,821.
Using the second model, the total cost of replacing ICD
generators in all patients except those for whom ICDFigure 2
Subsequent ICD Therapies After
Elective Generator Replacement
Patients with no ICD indication at the time of generator replacement subsequently
receive signiﬁcantly fewer ICD therapies compared with patients with an ICD
indication (2.8% vs. 10.7% per person-year, p < 0.001). ICD ¼ implantable
cardioverter-deﬁbrillator.
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2392therapy was considered not indicated (and explanting
generators in this group) was estimated at $4,049,797.45.
Using the third model, in which echocardiograms would
be obtained in the group of patients with unclear indica-
tions for ICD, and assuming that 26% (range 13% to 39%)
of these would be recategorized to the group for whom
ICD therapy was considered not indicated and these gen-
erators would then be explanted, the total cost was estimated
at $3,654,964.55 (range $3,839,962.95 to $3,399,310.50),
translating to a cost savings of $1,632,856.45 in the latter
group.
Discussion
The salient ﬁndings of our study are the following: 1) 26%
patients receiving initial ICD implants for primary preven-
tion in the setting of a low LVEF no longer meet guideline-
driven indications at the time of elective generator
replacement; and 2) these patients subsequently receive
appropriate ICD therapies at a signiﬁcantly lower rate than
patients who continued to meet primary prevention ICD
indications. These observations, to the best of our knowl-
edge, have never been previously reported.
Our study shows that a signiﬁcant proportion of patients
who receive their initial ICD for primary prevention on the
basis of a low LVEF undergo generator replacement despite
experiencing recovery of the LVEF to 40% and not
experiencing any ICD interventions in the intervening years.
Although the risk of SCD in patients who experience re-
covery of the LVEF is unknown and may still be higher than
in the general population, the current guidelines for primary
prevention ICD therapy are the same for patients under-
going initial implant or generator replacement. Similarly, the
Centers for Medicare & Medicaid Services National
Coverage Determination does not distinguish between ﬁrst
and subsequent implantations (15). Two recent studies
concluded that ICD pulse generators should be replaced even
if there is improvement in the LVEF after initial ICD im-
plantation (16,17). However, both are limited by relatively
small sample sizes and retrospective designs and base their
analyses on the delivery of ICD shocks, which may not be an
adequate surrogate for SCD (18,19). Furthermore, the lack of
an appropriate control group precludes any possible conclu-
sion of a mortality beneﬁt from these studies. Our study
showed that in patients who no longer fulﬁll primary pre-
vention ICD therapy indications at the time of generator
change, the subsequent rate of appropriate ICD therapies is
signiﬁcantly lower in patients who still meet these indications
(2.8% vs. 10.7% per person-year; log-rank, p < 0.001). This
ﬁnding would suggest that generator replacement may not
always need to be performed in this population and that the
lack of distinction between initial implantation and gener-
ator replacement in existing guideline criteria for appro-
priate use of primary prevention ICDs may be reasonable.
We also found that one-third of patients undergoing
elective replacement of devices that were originallyimplanted for primary prevention had not had a recent
assessment of their left ventricular function despite never
having received appropriate therapy from their ICD over the
lifetime of the device. Possible explanations for this may
include a lack of awareness on the part of healthcare pro-
viders that guideline criteria for primary prevention ICD
need revalidation at the time of generator replacement or the
perception that once implanted, ICD is a lifelong therapy.
However, in light of the ﬁndings of our study that shows
signiﬁcant improvement of left ventricular function in >25%
of patients undergoing initial ICD implantation for primary
prevention and that these patients subsequently receive
ICD therapies at a signiﬁcantly lower rate, an echocardio-
gram at the time when the original device reaches elective
replacement indications may be beneﬁcial. This is particu-
larly true for patients undergoing prophylactic ICD im-
plantation in the setting of an initial LVEF of 30% to 35%.
Reassessment of the LVEF before ICD generator replace-
ment may provide patients with more appropriate counseling
regarding the risk-beneﬁt proﬁle. Recent studies have shown
that patients undergoing ICD replacement may have double
the risk of pocket-related infections and/or require twice as
many surgical interventions for hematomas compared with
those undergoing initial ICD implantation (7,8). Further-
more, patients who undergo ICD replacement despite re-
covery of LVEF will continue to be at risk of inappropriate
shocks, which have been shown to have detrimental effects
on mortality, progression of heart failure, and psychological
well-being (10,11,20).
An important implication of our study pertains to the
healthcare costs of generator replacement in patients who
may no longer meet indications for primary prevention ICD
therapy. More than 100,000 ICDs are implanted in the
United States annually; of these procedures, w30,000 are
generator replacements (12). In our cohort alone, the cost
savings of not replacing ICD generators in patients who did
not meet criteria for ICD was >$1.5 million. In contrast,
the cost of obtaining echocardiograms, which are relatively
simple, noninvasive outpatient tests, to determine the LVEF
in patients about to undergo ICD replacement who never
received appropriate ICD therapies was <$50,000. These
cost calculations would favor an approach by which every
patient who receives an ICD for primary prevention and
who has not received appropriate ICD therapy over the
course of the original device life should undergo echocar-
diography when the battery reaches its elective replacement
or end-of-life indicator. It is also worth mentioning that
although initial ICD implantations for primary prevention
have been shown to be cost-effective for the numbers of lives
saved (21,22), the same may not be true after generator
replacement, especially among patients with improved
LVEF and/or those undergoing multiple (2) generator
replacements.
Although using the LVEF alone as a predictor of
arrhythmic death is ﬂawed, population studies have shown
quite clearly that patients with an LVEF of <30% to 35%
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2393have a much higher mortality, attributable in large part to
SCD, than patients with an LVEF >40% (23,24). Although
these studies examined the risk of mortality on the basis of
the initial LVEF, our observations further add to this and
suggest that LVEF improvement may impart a similar
decrease in the risk of SCD. Although the annual rate of
appropriate deﬁbrillator discharge in patients with primary
prevention ICDs in major trials is 5.1% (3), CRT re-
sponders who experience LVEF improvement to >45%
have an estimated 2-year risk of <3% for appropriate ICD
therapy, and CRT responders who experience complete
recovery of LVEF have a risk of SCD that is comparable
to the general population (25,26). These studies, as well as
our observations, make a case for performing ICD explan-
tation instead of generator replacement in patients who
experience no appropriate therapies and show signiﬁcant
improvement of the LVEF when their devices reach elective
replacement indications. In the patients in whom improve-
ment of LVEF has occurred with the original device being
CRT-D, a CRT without a deﬁbrillator (CRT-P) device
could be used instead of CRT-D for replacement.
Our study found that patients with an LVEF of 30% to
35% at the time of the initial ICD implantation were
signiﬁcantly more likely to not meet guideline-driven in-
dications for primary prevention ICD therapy at the time
of replacement compared with patients with an LVEF
of 15%. Interestingly, although patients with ICM were
more likely to meet guideline indications at the time of
generator replacement compared with patients with NICM
(22% vs. 33%), this difference did not reach statistical sig-
niﬁcance. Similarly, the type of the original device (CRT-D
vs. single- or dual-chamber ICD) was also not a predictor of
whether patients fulﬁlled guideline indications at the time
of generator change. The lack of a signiﬁcant difference in
some of these comparisons may be due to the small sample
size of our study.
Study limitations. This was a retrospective study of male
veterans that examined practice patterns at 2 medical cen-
ters, and these results may not be able to be extrapolated
to the general population. Although the CPRS system
comprehensively captures any care that the patients receive
within the VA system and non-VA health care records can
also be scanned into this system, it is possible that some
veterans may have received care outside of the VA system
that was not documented in the CPRS system, and these
data may have been missed. Because of the retrospective
nature of the study, we were unable to provide accurate data
regarding the speciﬁcs of ICD programming, which may
have affected the rate of appropriate ICD therapies. Our
cost calculations were relatively simple and did not take
into account the potential cost implications of pursuing
incidental ﬁndings that may be unmasked in patients
undergoing echocardiography before generator change.
Furthermore, even though this was a study of veteran
patients, we used Medicare physician and facility payment
rates for procedures. We used this method because VAhealthcare does not typically generate administrative claims
indicating the cost of medical care. Finally, although all
patients included in this analysis met guideline-derived
criteria for primary prevention ICD therapy, the retrospec-
tive nature of the study prevented us from being able to
determine accurately the time frame between the diagnosis
of cardiomyopathy and implantation of the original device
or validate optimization of medical therapy before to initial
ICD implantation.
Conclusions
Approximately 25% of patients who receive ICDs for pri-
mary prevention may no longer meet guideline-driven
indications for continued ICD use when their original bat-
teries reach elective replacement or end-of-life indicators.
These patients may subsequently receive fewer ICD therapies
than those who continue to meet indications. These ﬁndings
have important implications on healthcare costs. Large-scale
studies and/or prospective, randomized trials are needed to
determine the mortality beneﬁt and cost-effectiveness of
ICD replacement among patients who demonstrate
improvement in the LVEF after the initial implantation.
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